Richard Fruncillo, MD, PhD
Clinical Pharmacology & Toxicology
Dr. Richard Fruncillo has over 30 years of experience in clinical research. He joined CRI Lifetree as Senior Director, Early Phase Research, after spending almost 20 years as the head of Wyeth's Phase 1 Research Unit in Philadelphia where he was Principal Investigator for over 200 studies.
Dr. Fruncillo is Board Certified in Internal Medicine and Clinical Pharmacology. Dr. Fruncillo received a B.A. degree in Chemistry from the University of Pennsylvania, and an M.D. from Hahnemann University. He began his career in clinical research as a medical student and received the Upjohn Research Award for his work on drug metabolism in inflammation. Later, Dr. Fruncillo went on to complete a Family Medicine Internship and received a Ph.D. in Biochemical Pharmacology while at Hahnemann.
Subsequently, Dr. Fruncillo completed a fellowship in Clinical Pharmacology at Thomas Jefferson University where his research interest mainly involved Clinical Pharmacology of Cardiovascular agents. He then finished an Internal Medicine residency at Mercy Catholic Medical Center in Darby, Pennsylvania.
While at Wyeth, Dr. Fruncillo was Principal Investigator for many types of sophisticated Phase 1 studies, including first-in-man biologicals, CNS psychometric testing, elderly, renal failure, as well as many other complex therapeutic areas.
Dr. Fruncillo is the author or co-author of over 60 scientific articles, abstracts, and book chapters in the areas of Clinical Pharmacology, Toxicology, Pharmacokinetics, and Pain Management. He has received numerous awards in Chemistry, Pharmacology, and Clinical Research. He is currently a member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Phi, Beta Kappa, and American Mensa.